



(12) Translation of
European patent specification

(11) NO/EP 3265084 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/436 (2006.01)
A61K 31/519 (2006.01)

Norwegian Industrial Property Office

(45) Translation Published 2024.03.25

(80) Date of The European Patent Office Publication of the Granted Patent 2023.11.22

(86) European Application Nr. 16759417.5

(86) European Filing Date 2016.03.02

(87) The European Application's Publication Date 2018.01.10

(30) Priority 2015.03.03, US, 201562127717 P
2015.07.16, US, 201562193518 P

(84) Designated Contracting States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR

Designated Extension States: BA; ME

Designated Validation States: MA; MD

(73) Proprietor Pharmacyclics LLC, 1 N. Waukegan Road, North Chicago, IL 60064, USA

(72) Inventor ATLURI, Harisha, 310 Alto Maclane Street, Palo Alto, CA 94306, USA
CHONG, Ching, Wah, 3332 Kipling Place, Fremont, CA 94536, USA
KUEHL, Robert, 23 Medau Place, San Francisco, CA 94133, USA
TAN, Heow, 10094 Randy Lane, Cupertino, CA 95014, USA

(74) Agent or Attorney ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBTOR**

(56) References
Cited: US-A1- 2014 288 037
US-A1- 2012 071 497
WO-A1-2014/004707
WO-A1-2017/125423
US-A1- 2013 338 172
US-A1- 2015 031 710
WO-A1-2017/125424

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Fast tablettformulering omfattende:

(a) 70 vekt% ibrutinib,

5 (b) 14 vekt% laktosemonohydrat

(c) 5 vekt% mikrokrystallisk cellulose,

(d) 2 vekt% polyvinylpyrrolidon


(e) 7 vekt% krysskarmellosenatrium,

(f) 1 vekt% natriumlaurylsulfat,

10 (g) 0,5 vekt% kolloidalt silisiumdioksid, og

(h) 0,5 vekt% magnesiumstearat,

hvor ibrutinib er en forbindelse med strukturen til forbindelse 1,



Forbindelse 1;

15

og

hvor den faste tablettformuleringen er fremstilt med bruk av en fremgangsmåte omfattende en våtgranuleringsmetode.

20 2. Fast tablettformulering ifølge krav 1, hvor ibrutinib foreligger i en mengde på 35 mg til 840 mg per tablett.

3. Fast tablettformulering ifølge krav 2, hvor ibrutinib foreligger i en mengde på 35 mg, 70 mg, 140 mg, 280 mg, 420 mg, 560 mg eller 840 mg.

25

4. Fast tablettformulering ifølge krav 1, hvor ibrutinib foreligger i mikronisert form.

 5. Formulering for bruk i en fremgangsmåte ved behandling av en sykdom hos en pasient med behov for slik behandling, hvor formuleringen er en fast tablettformulering ifølge ethvert av de
- 5 foregående krav.